GRPZ - ETF AI Analysis
Top Page
Invesco S&P SmallCap 600 GARP ETF (GRPZ)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and in the last month, indicating positive recent momentum.
Leading Holdings Performing Well
Several of the largest positions, such as Powell Industries, International Seaways, and Tidewater, have delivered strong year-to-date results that support the fund’s overall performance.
Broad Sector Diversification Within Small Caps
The fund spreads its investments across many sectors—including financials, industrials, health care, consumer cyclical, energy, and technology—which helps reduce the impact of weakness in any single industry.
Negative Factors
Very Small Asset Base
The ETF manages a relatively low amount of assets, which can make it more vulnerable to trading liquidity issues and potential fund closure risk compared with larger funds.
High Concentration in U.S. Market
With almost all of its holdings in U.S. companies, the fund offers little geographic diversification and is heavily tied to the U.S. economic cycle.
Moderate Expense Ratio for a Passive ETF
The fund’s expense ratio is not especially low for an index-based ETF, meaning fees may take a somewhat larger bite out of long-term returns than cheaper alternatives.
GRPZ vs. SPDR S&P 500 ETF (SPY)
AUM3.25M
RegionNorth America
Expense Ratio0.35%
Beta0.92
IssuerInvesco
Inception DateMar 27, 2024
Dividend Yield0.89%
Asset ClassEquity
Index TrackedS&P SmallCap 600 GARP Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,376
30 Day Avg. Volume728
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
37.07Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering91
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GRPZ Summary
The Invesco S&P SmallCap 600 GARP ETF (GRPZ) follows the S&P SmallCap 600 GARP Index, focusing on smaller U.S. companies that are growing but still reasonably priced. It holds a mix of financial, industrial, health care, energy, and tech stocks, including names like Powell Industries and Clear Secure. Someone might consider this ETF to tap into the growth potential of small U.S. companies while spreading risk across many sectors. However, small-cap stocks can be more volatile than larger, well-known companies, so the value of this ETF can go up and down sharply with the market.
How much will it cost me?The Invesco S&P SmallCap 600 GARP ETF (GRPZ) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it tracks a specific index with a focus on small-cap companies and uses a more selective strategy. It’s still relatively affordable compared to actively managed funds.
What would affect this ETF?GRPZ could benefit from economic growth in the U.S., as small-cap companies often thrive during periods of expansion and innovation, particularly in sectors like Industrials and Technology, which are heavily weighted in the ETF. However, rising interest rates or economic slowdowns could negatively impact small-cap stocks, as these companies may face higher borrowing costs and reduced consumer demand, especially in sectors like Consumer Cyclical and Financials. Regulatory changes or shifts in energy policies could also affect holdings like Helmerich & Payne and International Seaways in the Energy sector.
GRPZ Top 10 Holdings
GRPZ leans heavily into U.S. small caps, with a clear tilt toward financials and health care names that are doing much of the heavy lifting. Fintech players like Sezzle and Dave have been rising, giving the fund a nice boost, while industrial-focused Argan and Powell Industries add steady power from the infrastructure side. On the health care front, TG Therapeutics and Krystal Biotech are helping, even as TransMedics and insurers like Palomar look a bit mixed and occasionally drag on returns. Overall, it’s a domestically focused, growth-at-a-decent-price story with no single stock dominating the show.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Sezzle Inc. | 2.26% | $73.59K | $6.16B | -1.35% | 80 Outperform | |
| Dave | 2.08% | $67.72K | $4.92B | 41.53% | 80 Outperform | |
| Millrose Properties Inc Class A | 1.91% | $62.30K | $4.59B | 3.13% | ― | |
| Palomar Holdings | 1.83% | $59.84K | $3.71B | -2.20% | 83 Outperform | |
| Cal-Maine Foods | 1.77% | $57.67K | $3.97B | -16.57% | 84 Outperform | |
| TG Therapeutics | 1.75% | $56.97K | $8.16B | 54.17% | 65 Neutral | |
| Krystal Biotech | 1.73% | $56.58K | $11.06B | 157.16% | 80 Outperform | |
| Argan | 1.67% | $54.39K | $9.90B | 227.45% | 73 Outperform | |
| Inspire Medical Systems | 1.64% | $53.50K | $1.35B | -61.04% | 73 Outperform | |
| ADMA Biologics | 1.59% | $51.91K | $2.07B | -48.57% | 78 Outperform |
GRPZ Technical Analysis
Positive
―
Price Trends
30.32
Positive
29.21
Positive
28.07
Positive
Market Momentum
0.66
Negative
66.31
Neutral
47.17
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GRPZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.44, equal to the 50-day MA of 30.32, and equal to the 200-day MA of 28.07, indicating a bullish trend. The MACD of 0.66 indicates Negative momentum. The RSI at 66.31 is Neutral, neither overbought nor oversold. The STOCH value of 47.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRPZ.
GRPZ Peer Comparison
Comparison Results
Performance Comparison
GRPZ
Invesco S&P SmallCap 600 GARP ETF
32.26
6.83
26.86%
AIMS
Acuitas Small Cap Active ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents